Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month
March 01, 2021 08:00 ET
|
Caelum Biosciences, Inc.
BORDENTOWN, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today...
Caelum Biosciences Announces Two Oral Presentations of Additional Data from Phase 1b Study of Anti-Amyloid mAb CAEL-101 and Preclinical Imaging Study at 60th American Society of Hematology Annual Meeting
December 04, 2018 08:00 ET
|
Caelum Biosciences, Inc.
Phase 1b data confirm efficacy in AL Amyloidosis with two cardiac markers correlated with survival Preclinical data demonstrate the potential of using radiolabeled CAEL-101 for real-time imaging of...
Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentations at 60th American Society of Hematology Annual Meeting
November 02, 2018 08:00 ET
|
Caelum Biosciences, Inc.
NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a company focused on developing treatments for rare and life-threatening diseases, today announced that additional...
Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis
June 25, 2018 07:30 ET
|
Caelum Biosciences, Inc.
Nine of 10 cardiac patients on CAEL-101 showed improvement in global longitudinal strain CAEL-101 led to sustained decrease in NT-proBNP levels Data presented at American Society of Echocardiography...
Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions
June 18, 2018 07:30 ET
|
Caelum Biosciences, Inc.
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today...
Caelum Biosciences Submits Draft Registration Statement on Form S-1 to the Securities and Exchange Commission
April 20, 2018 22:00 ET
|
Caelum Biosciences, Inc.
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. Company developing treatments for rare and life-threatening diseases, today announced it...
Caelum Biosciences Announces Updated Phase 1b Data Presented at 16th International Symposium on Amyloidosis
March 27, 2018 08:00 ET
|
Caelum Biosciences, Inc.
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today...
Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis
March 21, 2018 08:00 ET
|
Caelum Biosciences, Inc.
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today...
Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis
December 11, 2017 08:00 ET
|
Caelum Biosciences, Inc.
Eight of 12 patients (67 percent) with cardiac involvement responded to therapy with a median time to cardiac response of 21 days 14 of 24 (63 percent) of patients demonstrated organ response ...
Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting
November 01, 2017 09:05 ET
|
Caelum Biosciences, Inc.
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company focused on developing treatments for rare and life-threatening...